Modern pharmacotherapy of neoplastic diseases is based on schemes which have been used in medicine for many years, e.g. CMF (cyclophosphamide, methotrexate, 5-fluorouracil), AC (cyclophosphamide, doxorubicin), EC (epirubicin, cyclophosphamide) with a large percentage of positive systemic responses. The search continues to find new particles capable of blocking the invasive or metastatic character of the tumour at specific stages of its development. In recent years we have been observing increased interest in antiangiogenic therapy. The most important factor affecting the formation of new blood vessels is VEGF – Vascular Endothelial Growth Factor. In experimental research blocking VEGF leads to reduced intratissue pressure and improves the penetration of cytostatic drugs into the tumour tissue. The introduction of angiogenesis inhibitors made a breakthrough in the treatment of malignant tumours. It contributed to the reduction of prevalence and mortality rates and extended the survival period. The antiangiogenic therapy applies such drugs as: bevacizumab, sunitinib, sorafenib and vatalanib. Arterial hypertension is one of the most common complications of the systemic blockade of signal transmission along the route of the endothelial growth factor. The frequency of occurrence and intensity of arterial hypertension in oncological patients depends on the type of applied drugs, doses, dosage schemes, patients’ age and concomitance of heart diseases.